WebMCE (MedChemExpress) 为生命科学和医药研发人员提供 50,000+ 特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。全球文献广泛引用，质控体系严格，100%客户满意保障。 Web1.cyp1a2抑制剂：cyp1a2抑制剂主要有抗抑郁药 氟伏沙明、喹诺酮类抗生素及非选择性的肝药酶抑制剂西咪替丁等，因茶碱、华法林、咖啡因等药物安全性较低，药酶抑制剂可使 …

调节生物钟节律的靶标及其药物研发进展 药时代

WebJul 23, 2024 · 随着国家医保政策对抗癌药物的大力支持，很多新型靶向药物不断地在中国上市，好多还进入了医保报销目录，极大地缓解了中国大多数癌症患者无药可用和用不起药的局面。 吉非替尼和厄洛替尼是目前治疗肺癌的最常用… WebNov 14, 2024 · 随着分子靶向治疗研究的进展，越来越多的新靶点、新靶向药物加入了这个抗癌的“大家庭”当中。每个靶点各有特点、每款药物各有所长，今天小汇要为大家介绍的，是一个常于肿瘤相关巨噬细胞中过表达的基因，csf1r基因。 csf1r：肿瘤相关巨噬细胞中过表达的 … order from walmart canada

CYP11A1 inhibition as a therapeutic approach for the …

WebCYP17A1 inhibitor. Abiraterone acetate, a steroidal CYP17A1 inhibitor that is used in the treatment of prostate cancer. A CYP17A1 inhibitor is a type of drug which inhibits the enzyme CYP17A1. [1] It may inhibit both of the functions of the enzyme, 17α-hydroxylase and 17,20-lyase, or may be selective for inhibition of one of these two ... Web聚焦"合成致死"策略，英矽智能发现靶向USP1的临床前候选药物，用于多种抗肿瘤疗法开发. 我们很高兴地宣布，英矽智能提名了一款靶向合成致死靶点去泛素化酶（USP1）的临床前候选药物用于抗肿瘤治疗。. 该候选药物是一款由AI设计并经由临床前实验验证、具有 ... A CYP17A1 inhibitor is a type of drug which inhibits the enzyme CYP17A1. It may inhibit both of the functions of the enzyme, 17α-hydroxylase and 17,20-lyase, or may be selective for inhibition of one of these two functions (generally 17,20-lyase). These drugs prevent the conversion of pregnane steroids into androgens like testosterone and therefore are androgen biosynthesis inhibitors and functional iready my stuff